Fosamax Osteonecrosis of the Jaw Attorney: Statute of Limitations for Fosamax in Texas

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Awareness to Specific Medication Risks

For decades, general health and science information has served as a foundational resource for public awareness, offering broad guidance on wellness, disease prevention, and the safe use of medications. Within this legacy framework, audiences have been educated about the importance of adhering to prescribed treatments and recognizing potential side effects. This heritage of informed decision-making naturally extends to more specialized areas of pharmaceutical safety, where long-term medication use may intersect with unexpected health outcomes. As the public has become more attuned to the nuances of drug therapies, attention has shifted toward specific patient populations and their unique exposure histories. In the context of mass production and widespread prescription, certain medications—such as bisphosphonates used for bone density management—have prompted closer scrutiny of their risk profiles. This is particularly relevant when considering occupational or therapeutic exposure over extended periods. The transition from general health literacy to a focused concern about medication-related risks is a logical progression, especially when legal and medical questions arise regarding timely action. For individuals who have used such therapies, understanding the temporal boundaries for seeking recourse becomes critical. Thus, the legacy of general health education now converges with a targeted inquiry into the statute of limitations for legal claims in Texas, specifically for those who have experienced adverse outcomes linked to prolonged bisphosphonate use.

Understanding Fosamax and Its Link to Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ often involves pain, swelling, infection, and exposed bone in the mandible or maxilla, and diagnosis is typically made through clinical examination and imaging. The mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast-mediated bone resorption. Bisphosphonates like Fosamax accumulate in bone and suppress bone turnover, which can impair the jaw's ability to repair microdamage and respond to local infections or trauma. This is particularly relevant in the jaw, where high bone turnover occurs due to dental procedures and daily mechanical stress. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Clinical Evidence and Risk Context

The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The incidence of ONJ is considered rare, with one study noting that the incidence of atypical femoral fracture or osteonecrosis of the jaw was uncommon and rare, respectively (https://pubmed.ncbi.nlm.nih.gov/42046648/). The same study found that fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years, after either three or five years of prescription (https://pubmed.ncbi.nlm.nih.gov/42046648/). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning under section 5.4 about osteonecrosis of the jaw, stating that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also states that the optimal duration of use has not been determined, and for patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while warnings exist, the timeline between exposure and documented harm can be variable, and patients may not always be fully informed of the risk, especially if they are not undergoing dental procedures.

Statute of Limitations for Fosamax Claims in Texas

For affected patients in Texas considering legal action, the statute of limitations for personal injury claims, including those related to Fosamax and ONJ, is generally two years from the date the injury was discovered or should have been discovered. This timeline is critical because ONJ can develop months or years after starting Fosamax, and patients may not immediately connect their jaw symptoms to the medication. Attorney-related considerations include the need to document the timeline of Fosamax use, the onset of ONJ symptoms, and any dental procedures or other risk factors. The evidence shows that the time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), and that the risk of ONJ may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients should also be aware that discontinuation of bisphosphonate treatment may reduce the risk for ONJ if invasive dental procedures are needed (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In summary, Fosamax is associated with a rare but serious risk of ONJ, with variable onset and multiple risk factors. The prescribing information includes warnings, but the adequacy of these warnings may be questioned in cases where patients were not informed of the risk before developing ONJ. Patients in Texas should be aware of the two-year statute of limitations and seek legal counsel promptly if they believe they have been harmed.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in Texas?

In Texas, the statute of limitations for personal injury claims, including those related to Fosamax and osteonecrosis of the jaw (ONJ), is generally two years from the date the injury was discovered or should have been discovered. It is important to consult with an attorney promptly to ensure your claim is filed within this timeframe.

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors for ONJ include invasive dental procedures (such as tooth extraction or dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.